Lyme Disease Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight's, "Lyme Disease Pipeline Insight" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lyme Disease (LD) pipeline landscape. It covers the Lyme Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lyme Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Lyme Disease Pipeline Outlook Report [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Lyme Disease Pipeline Report

* In December 2024, ModernaTX Inc . initiated a Phase 1/2 randomized, observer-blind, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of Heptavalent mRNA-1975 (SR1-7) and Monovalent mRNA-1982 (SR1) vaccines against Lyme disease in healthy participants aged 18 to 70 years.
* DelveInsight's Lyme Disease pipeline report depicts a robust space with 7+ active players working to develop 7+ pipeline therapies for Lyme Disease treatment.
* The leading Lyme Disease Companies such as Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics , and others.
* Promising Lyme Disease Therapies such as VLA15, mRNA-1975, Low Dose TP-05 and others.

Learn how leading Lyme Disease Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Lyme Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Lyme Disease Emerging Drugs

* VLA 15: Valneva

VLA15 is currently the only active vaccine program in clinical development against Lyme disease. VLA15 is a multivalent recombinant protein vaccine that targets six serotypes of Borrelia representing the most common pathogenic strains found in the United States and Europe. Valneva has completed recruitment and reported initial results for two Phase 2 clinical trials of VLA15 in over 800 healthy adults and in which Valneva observed high levels of antibodies against all six serotypes. Valneva announced a collaboration with Pfizer for late phase development and, if approved, commercialization of VLA15.

* CT38: Cortene

CT38 is a potent, short-lived, peptide agonist selective for CRFR2. It is comprised entirely of naturally-occurring amino acids. It was tested in animals and in healthy humans in a Phase 1 clinical trial. These studies have defined the safety profile of CT38 in humans and show that CT38 only lasts a few hours in the body.

The Lyme Disease pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Lyme Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lyme Disease Treatment.
* Lyme Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Lyme Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lyme Disease market.

From early-stage research to late-phase Lyme Disease Clinical Trials, our analysis covers key Lyme Disease Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Lyme Disease Treatment Drugs [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Lyme Disease Companies

Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics and others.

Lyme Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.

Lyme Disease Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Stay updated with the latest Lyme Disease Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Lyme Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Lyme Disease Pipeline Report

* Coverage- Global
* Lyme Disease Companies- Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics , and others.
* Lyme Disease Therapies- VLA15, mRNA-1975, Low Dose TP-05 and others.
* Lyme Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Lyme Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Lyme Disease Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Lyme Disease Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Lyme Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Lyme Disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* VLA 15: Valneva
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CT 38: Cortene
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Lyme disease vaccine - Introvacc
* Drug profiles in the detailed report.....
* Inactive Products
* Lyme Disease Key Companies
* Lyme Disease Key Products
* Lyme Disease- Unmet Needs
* Lyme Disease- Market Drivers and Barriers
* Lyme Disease- Future Perspectives and Conclusion
* Lyme Disease Analyst Views
* Lyme Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lyme-disease-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bone-growth-stimulators-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.